公开(公告)号：US20230382972A9

公开(公告)日：2023-11-30

申请号：US17773800

申请日：2020-11-04

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Hong XIANG ,  Siddhartha MITRA

IPC: C07K14/705 ,  A61P35/00

CPC classification number: C07K14/70532 ,  A61P35/00 ,  A61K2039/505

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.

公开(公告)号：US11447553B2

公开(公告)日：2022-09-20

申请号：US15358756

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Kristen Pierce ,  Janine Powers ,  Servando Palencia ,  Robert Sikorski ,  Majid Ghoddusi ,  Kartik Krishnan

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  G01N33/50 ,  G01N33/574

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US11235059B2

公开(公告)日：2022-02-01

申请号：US16181784

申请日：2018-11-06

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Kristen Pierce ,  Namrata Patil ,  Thomas Brennan ,  Julie Hambleton

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00 ,  A61K33/243 ,  A61K31/337 ,  A61K31/513 ,  A61K45/06

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

公开(公告)号：US20220010020A1

公开(公告)日：2022-01-13

申请号：US17282589

申请日：2019-10-04

Applicant: Five Prime Therapeutics, Inc.

Inventor： Isaias Prado ,  Chin-Yi Huang

IPC: C07K16/28 ,  A61K47/26 ,  A61K47/18

Abstract: This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.

公开(公告)号：US20210317219A1

公开(公告)日：2021-10-14

申请号：US17183734

申请日：2021-02-24

Applicant: Five Prime Therapeutics, Inc.

Inventor： Julie Hambleton ,  Emma Masteller ,  James Zanghi ,  Robert Sikorski ,  Hong Xiang

IPC: C07K16/28

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

公开(公告)号：US20210277130A1

公开(公告)日：2021-09-09

申请号：US17173886

申请日：2021-02-11

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Justin Wong ,  Haishan Lin

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

公开(公告)号：US11098103B2

公开(公告)日：2021-08-24

申请号：US16354689

申请日：2019-03-15

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K16/00 ,  C07K16/28 ,  A61K38/00

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US11091555B2

公开(公告)日：2021-08-17

申请号：US16613579

申请日：2018-05-15

Applicant: Five Prime Therapeutics, Inc.

Inventor： Helen L. Collins ,  James Hnatyszyn ,  Hong Xiang ,  Xiang Zhang

IPC: C07K16/28 ,  A61P35/04 ,  A61P35/00 ,  A61K9/00 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519 ,  A61K39/395 ,  A61K39/00

Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

公开(公告)号：US20210070861A1

公开(公告)日：2021-03-11

申请号：US16997577

申请日：2020-08-19

Applicant: Five Prime Therapeutics, Inc.

Inventor： Yong QUAN ,  Chin-Yi HUANG ,  Harjeet Singh GANDA

IPC: C07K16/28 ,  A61K47/12 ,  A61K47/26 ,  A61K47/22 ,  A61K47/02

Abstract: The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4). The present disclosure also prides methods for treating disorders, such as cancer, by administering such pharmaceutical compositions.

公开(公告)号：US20210017283A1

公开(公告)日：2021-01-21

申请号：US16982277

申请日：2019-03-19

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Xiaodi Deng ,  Lin Hui Su ,  Ginger Rakestraw ,  Jason R. Pinckney ,  David A. Critton ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova

IPC: C07K16/28 ,  C07K16/46 ,  A61K38/16

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.